168 related articles for article (PubMed ID: 8878001)
1. Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis.
Protzer U; Dienes HP; Bianchi L; Lohse AW; Helmreich-Becker I; Gerken G; Meyer zum Büschenfelde KH
Liver; 1996 Aug; 16(4):274-82. PubMed ID: 8878001
[TBL] [Abstract][Full Text] [Related]
2. Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced primary sclerosing cholangitis.
Beuers U; Spengler U; Sackmann M; Paumgartner G; Sauerbruch T
J Hepatol; 1992 May; 15(1-2):140-3. PubMed ID: 1506631
[TBL] [Abstract][Full Text] [Related]
3. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.
Gohlke F; Lohse AW; Dienes HP; Löhr H; Märker-Hermann E; Gerken G; Meyer zum Büschenfelde KH
J Hepatol; 1996 Jun; 24(6):699-705. PubMed ID: 8835745
[TBL] [Abstract][Full Text] [Related]
4. Predictors of successful clinical and laboratory outcomes in patients with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography.
Enns R; Eloubeidi MA; Mergener K; Jowell PS; Branch MS; Baillie J
Can J Gastroenterol; 2003 Apr; 17(4):243-8. PubMed ID: 12704468
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.
Lüth S; Kanzler S; Frenzel C; Kasper HU; Dienes HP; Schramm C; Galle PR; Herkel J; Lohse AW
J Clin Gastroenterol; 2009 Jan; 43(1):75-80. PubMed ID: 18769363
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid.
Li CP; Tong MJ; Hwang SJ; Luo JC; Co RL; Tsay SH; Chang FY; Lee SD
J Gastroenterol Hepatol; 2000 Jan; 15(1):95-8. PubMed ID: 10719755
[TBL] [Abstract][Full Text] [Related]
7. Syncytial giant-cell hepatitis--a specific disease entity?
Lau JY; Koukoulis G; Mieli-Vergani G; Portmann BC; Williams R
J Hepatol; 1992 May; 15(1-2):216-9. PubMed ID: 1506641
[TBL] [Abstract][Full Text] [Related]
8. [Primary sclerosing cholangitis (PSC)].
Takagi I; Shibamoto Y; Toda G
Ryoikibetsu Shokogun Shirizu; 2000; (31):226-9. PubMed ID: 11269064
[No Abstract] [Full Text] [Related]
9. Autoimmune hepatitis with giant-cell transformation.
Estradas J; Pascual-Ramos V; Martínez B; Uribe M; Torre A
Ann Hepatol; 2009; 8(1):68-70. PubMed ID: 19221538
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
[TBL] [Abstract][Full Text] [Related]
11. Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases.
Griga T; Tromm A; Müller KM; May B
Eur J Gastroenterol Hepatol; 2000 May; 12(5):559-64. PubMed ID: 10833101
[TBL] [Abstract][Full Text] [Related]
12. Primary sclerosing cholangitis in children.
Roberts EA
J Gastroenterol Hepatol; 1999 Jun; 14(6):588-93. PubMed ID: 10385070
[TBL] [Abstract][Full Text] [Related]
13. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine.
Kozaiwa K; Tajiri H; Sawada A; Tada K; Etani Y; Miki K; Okada S
J Gastroenterol Hepatol; 1998 Aug; 13(8):825-9. PubMed ID: 9736177
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.
Davies YK; Cox KM; Abdullah BA; Safta A; Terry AB; Cox KL
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):61-7. PubMed ID: 18607270
[TBL] [Abstract][Full Text] [Related]
15. [Review of overlap syndromes in autoimmune liver diseases. Diagnostic and therapeutic difficulties].
Hagymási K; Tulassay Z
Orv Hetil; 2013 Jun; 154(24):923-9. PubMed ID: 23752047
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune hepatitis 2 years after the diagnosis of primary sclerosing cholangitis: an unusual overlap syndrome in a 17-year-old adolescent.
Mueller T; Bianchi L; Menges M
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):232-6. PubMed ID: 18301306
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
18. Hepatic failure after injury - a common pathogenesis with sclerosing cholangitis?
Zilkens C; Friese J; Köller M; Muhr G; Schinkel C
Eur J Med Res; 2008 Jul; 13(7):309-13. PubMed ID: 18700186
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.
De Maria N; Colantoni A; Rosenbloom E; Van Thiel DH
Hepatogastroenterology; 1996; 43(12):1472-9. PubMed ID: 8975951
[TBL] [Abstract][Full Text] [Related]
20. An atypical presentation for primary sclerosing cholangitis.
Luketic VA; Gomez DA; Sanyal AJ; Shiffman ML
Dig Dis Sci; 1997 Oct; 42(10):2009-16. PubMed ID: 9365127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
